Cagrilintide and semaglutide together drive record weight loss in global trial Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors Nature Communications Zepbound Outperforms CagriSema in Head to Head Phase III Obesity Trial PDF] Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial. Semantic Scholar Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination